The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2023

Filed:

Jun. 21, 2018
Applicant:

Catholic University Industry Academic Cooperation Foundation, Seoul, KR;

Inventors:

Sung Won Kim, Seoul, KR;

Seung Ki Kwok, Seoul, KR;

Jaeseon Lee, Seoul, KR;

Sun hwa Park, Seoul, KR;

Jung Yeon Lim, Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); A61P 19/02 (2006.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61P 19/02 (2018.01);
Abstract

The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4CD25foxp3cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.


Find Patent Forward Citations

Loading…